within Pharmacolibrary.Drugs.ATC.B;

model B03AA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ferrous sodium citrate is an iron supplement used to treat or prevent iron deficiency anemia. It is a water-soluble salt of iron that is sometimes used in oral formulations. Its use is mostly limited to dietary supplements and is not widely approved as a prescription drug in most countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults, as specific data is not reported in literature sources.</p><h4>References</h4><ol><li><p>Motoya, T, et al., &amp; Yamada, K (2000). Effects of ascorbic acid on interactions between ciprofloxacin and ferrous sulphate, sodium ferrous citrate or ferric pyrophosphate, in mice. <i>The Journal of pharmacy and pharmacology</i> 52(4) 397–401. DOI:<a href=&quot;https://doi.org/10.1211/0022357001774147&quot;>10.1211/0022357001774147</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10813549/&quot;>https://pubmed.ncbi.nlm.nih.gov/10813549</a></p></li><li><p>Yadav, V, et al., &amp; Basit, AW (2021). 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. <i>Biomedicines</i> 9(5) –. DOI:<a href=&quot;https://doi.org/10.3390/biomedicines9050578&quot;>10.3390/biomedicines9050578</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34065300/&quot;>https://pubmed.ncbi.nlm.nih.gov/34065300</a></p></li><li><p>Kokado, Y, et al., &amp; Kondo, K (2021). In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. <i>Clinical therapeutics</i> 43(8) 1408–1418.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2021.06.013&quot;>10.1016/j.clinthera.2021.06.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34511184/&quot;>https://pubmed.ncbi.nlm.nih.gov/34511184</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03AA12;
